U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07262476) titled 'Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease' on Nov. 20.
Brief Summary: This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease (TED)
Intervention:
DRUG: MHB018A injection
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd
Disclaimer: Curated by HT Syndication....